| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-106 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 2025 年度关联交易确认及 2026 年度日常关联交易预计公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 青岛百洋医药股份有限公司（以下简称"公司"）根据《中华人民共和国公 司法》《深圳证券交易所创业板股票上市规则》等相关法律法规、规范性文件及 《公司章程》有关规定，结合日常经营和业务发展需要，预计 2026 年度公司及 子公司将与关联人发生的日常关联交易金额不超过 93,769.00 万元。公司 2025 年度日常关联交易预计金额为 97,660.00 万元，2025 年 1-11 月实际发生金额为 52,757.31 万元。 2025 年 12 月 30 日，公司召开第四届董事会第四次会议，以 3 票赞成、0 票反对、0 票弃权的表决结果审议通过了《关于 2025 年度关联交易确认及 20 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-105 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 关于与专业投资机构共同投资暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、与专业投资机构共同投资暨关联交易概述 （一）交易的基本情况 为实现产业战略布局，把握战略合作机会，充分借助专业投资机构的资源优 势和专业能力，优化青岛百洋医药股份有限公司（以下简称"公司"、"上市公司"） 产业布局，公司拟与苏州百洋非凡企业管理有限公司（以下简称"百洋非凡"）、 苏州国发资产管理有限公司、苏州飞凡资产管理有限公司、苏州国发新创产业叁 号投资企业（有限合伙）、苏州工业园区创业投资引导基金合伙企业（有限合伙） 共同出资设立苏州百洋股权投资基金合伙企业（有限合伙）（暂定名，最终以工 商登记为准，以下简称"苏州百洋基金"）。百洋非凡、苏州国发资产管理有限公 司为苏州百洋基金的普通合伙人，百洋非凡为苏州百洋基金的执行事务合伙人， 其他投资方为苏州百洋 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-104 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 关于部分募投项目延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛百洋医药股份有限公司（以下简称"公司"）于 2025 年 12 月 30 日召 开第四届董事会第四次会议，审议通过了《关于部分募投项目延期的议案》，同 意对公司向不特定对象发行可转换公司债券（以下简称"可转债"）募投项目"百 洋云化系统升级项目"达到预定可使用状态时间进行延期。本次部分募投项目延 期不涉及变更募集资金的用途，在董事会审批权限内，无需提交股东会审议。具 体情况如下： 一、募集资金基本情况 （一）募集资金到账情况 经中国证券监督管理委员会《关于同意青岛百洋医药股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可[2023]613号）同意注册，公司 向不特定对象发行可转债860万张，每张面值为人民币100元，募集资金总额为人 民币86,000.00 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、关联交易概述 为优化资产结构，提高资产运营效率，青岛百洋医药股份有限公司（以下简 称"公司"）于 2025 年 10 月 29 日召开第四届董事会第二次会议，审议通过了《关 于出售参股公司股权暨关联交易的议案》，同意公司与北京百洋家健康管理有限 公司（以下简称"百洋家健康"）签订《股权转让协议》，将公司持有的北京五维 康科技有限公司（以下简称"五维康"）40.0465%股权以 57,461,562.80 元的价格 转让给百洋家健康。具体内容详见公司于 2025 年 10 月 30 日在巨潮资讯网 （www.cninfo.com.cn）披露的《青岛百洋医药股份有限公司关于出售参股公司股 权暨关联交易的公告》。 | 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-108 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 关于出售参股公司股权暨关联交易的进展公告 截至本公告披露日，公司已与协议各方签署《股权转让协 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of December 28, 2025 [1] Core Insights - The report highlights the intensive policy support for brain-computer interface (BCI) technology development, particularly in the medical field, with several policies already implemented [2] - It emphasizes the significant market opportunity in radiation therapy equipment, particularly the ZAP-X system, which is expected to capture a substantial share of the growing market for non-invasive tumor radiation treatment [3] - The introduction of pathology fee reforms is seen as a breakthrough for the commercialization of AI applications in pathology, allowing for better integration of AI-assisted diagnostics into the pricing structure [5] - The report discusses the trend of Chinese innovative drugs entering international markets, which is expected to reduce domestic competition and provide new valuation anchors for these companies [6] - It also notes the promising developments in oral autoimmune drugs and small nucleic acid drugs, with several companies making significant progress in clinical trials [7][9] Summary by Sections 1. Policy Support for BCI Technology - In July 2025, a joint opinion was issued by multiple government departments to promote BCI industry innovation, with medical health being a core application area [2] - The National Medical Products Administration (NMPA) has prioritized the approval of implantable BCI medical devices, with expected registration certificates to be issued by Q1 2026 [2] 2. Radiation Therapy Equipment Market - The ZAP-X system is designed for precise radiation therapy for brain tumors, with a significant patient population in China, estimated at 1.5 million new cases of brain metastases annually [3] - The non-invasive tumor radiation treatment market is projected to grow from RMB 27.2 billion in 2018 to RMB 59.4 billion by 2024, with a compound annual growth rate (CAGR) of 13.9% [3] 3. AI in Pathology - The NMPA's new guidelines for pathology services include AI-assisted diagnostics as an expansion item, which will help streamline the commercialization of AI technologies in pathology [5] 4. Innovative Drug Exports - The report notes that partnerships between Chinese companies and international firms are increasing, providing funding and reducing competition in the domestic market [6] - The innovative drug index has risen by 38.11% since the beginning of 2025, outperforming the CSI 300 index [6] 5. Oral Autoimmune Drugs - Takeda's new oral TYK2 inhibitor has shown positive results in clinical trials for psoriasis, indicating a potential breakthrough in treatment options [7] - Several domestic companies are also advancing in the development of oral autoimmune drugs targeting various conditions [7] 6. Small Nucleic Acid Drugs - Yuyuan Pharmaceutical's YKYY032 injection has received clinical approval from both the FDA and NMPA, with multiple companies in China advancing in the small nucleic acid drug space [9] - The report highlights the reliability of domestic technology platforms as they progress through clinical trials [9] 7. Stock Recommendations - The report recommends specific companies based on the identified opportunities, including Meihua Medical for BCI technology, Baiyang Pharmaceutical for ZAP-X, and Yuyuan Pharmaceutical for small nucleic acid drugs [11]

证券之星消息，12月25日医药商业板块较上一交易日上涨0.41%，合富中国领涨。当日上证指数报收于 3959.62，上涨0.47%。深证成指报收于13531.41，上涨0.33%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603122 | 合富中国 | 26.04 | 5.25% | 90.01万 | 22.46 乙 | | 301015 | 百洋医药 | 24.22 | 2.98% | 7.45万 | 1.80亿 | | 600538 | 国发股份 | 6.35 | 2.58% | 9.20万 | 5782.41万 | | 300937 | 药易购 | 35.16 | 2.36% | 11.03万 | 3.89亿 | | 002788 | 營荷医药 | 20.06 | 2.09% | 101.86万 | 19.77亿 | | 603716 | 塞力医疗 | 22.02 | 1.71% | 20.62万 | 4.51亿 | | 603939 | 益丰药房 | ...

格隆汇12月23日丨百洋医药(301015.SZ)在投资者互动平台表示，易复诊为公司控股股东投资的企业， 目前公司未与蚂蚁阿福合作。 ...

格隆汇12月23日丨百洋医药(301015.SZ)在投资者互动平台表示，易复诊为公司控股股东投资的企业， 目前公司未与蚂蚁阿福合作。 ...

证券代码：301015 证券简称：百洋医药 公告编号：2025-102 债券代码：123194 债券简称：百洋转债 青岛百洋医药股份有限公司 关于子公司为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，为满足子公司业务发展的资金需求，青岛百洋医药股份有限公司（以下 简称"公司"）控股子公司上海百洋制药股份有限公司（以下简称"百洋制药"） 为其全资子公司上海百洋制药科技有限公司（以下简称"上海制药"）提供了连带 责任保证担保。具体情况如下： 一、担保情况概述 公司分别于 2025 年 4 月 22 日召开第三届董事会第三十一次会议、2025 年 5 月 14 日召开 2024 年年度股东大会，审议通过了《关于 2025 年度对外担保额度预计的 议案》，同意百洋制药为上海制药提供不超过 40,200 万元的担保额度，担保额度的 有效期为自 2024 年年度股东大会决议通过之日起 12 个月。具体内容详见公司在巨 潮资讯网（www.cninfo.com.cn）披露的相关公告。 二、担保进展情况 近日，为满足日常经营需求，上海制药向招商 ...

Core Viewpoint - Baiyang Pharmaceutical is advancing its "big radiotherapy" strategy with the ZAP-X Mars surgical robot, focusing on precision radiotherapy and establishing a comprehensive global supply chain and clinical research framework [2][3]. Group 1: Product Development and Market Strategy - Baiyang Pharmaceutical has made significant progress with the ZAP-X, including the launch of global manufacturing bases, initiation of clinical research, and establishment of radiotherapy centers [2]. - The company has invested in ZAP Surgical in Silicon Valley to oversee the commercialization of ZAP-X in China and to initiate global-scale production [5]. - ZAP-X has been approved for sale in 24 countries and regions, with over 5,000 clinical applications recorded [6]. Group 2: Clinical Application and Research - Baiyang Pharmaceutical is addressing the challenge of brain metastases, which sees 1.5 million new cases annually in China, by promoting ZAP-X's clinical application [5]. - The company is collaborating with hospitals to create independent third-party precision radiotherapy centers, aiming to establish 15 centers by the end of 2026 [6]. - Real-world studies and investigator-initiated trials (IIT) are being launched to validate ZAP-X's clinical value and integrate it into China's clinical research system [7]. Group 3: Technological Innovation and Future Trends - Baiyang Pharmaceutical is expanding its precision radiotherapy portfolio to include specialized devices for brain, body, and cardiac applications [8]. - The company has developed China's first 4π intelligent robotic radiotherapy system, enhancing treatment precision and reducing side effects [8]. - Ongoing research in non-invasive cardiac radiotherapy is expected to pioneer new treatment methods for arrhythmias [8].